Manfredi Mariangela, Van Hoovels Lieve, Benucci Maurizio, De Luca Riccardo, Coccia Carmela, Bernardini Pamela, Russo Edda, Amedei Amedeo, Guiducci Serena, Grossi Valentina, Bossuyt Xavier, Perricone Carlo, Infantino Maria
Immunology and Allergology Laboratory Unit, S. Giovanni di Dio Hospital, 50143 Florence, Italy.
Department of Microbiology, Immunology and Transplantation, University of Leuven, 3000 Leuven, Belgium.
J Pers Med. 2023 Apr 19;13(4):688. doi: 10.3390/jpm13040688.
The soluble urokinase plasminogen activator receptor (suPAR) is the bioactive form of uPAR, a membrane-bound glycoprotein, and it is primarily expressed on the surface of immunologically active cells. Mirroring local inflammation and immune activation, suPAR has gained interest as a potential prognostic biomarker in several inflammatory diseases. Indeed, in many diseases, including cancer, diabetes, cardiovascular diseases, kidney diseases, and inflammatory disorders, higher suPAR concentrations have been associated with disease severity, disease relapse, and mortality. Our review describes and discusses the supporting literature concerning the promising role of suPAR as a biomarker in different autoimmune rheumatic and non-rheumatic diseases.
可溶性尿激酶型纤溶酶原激活物受体（suPAR）是膜结合糖蛋白uPAR的生物活性形式，主要在免疫活性细胞表面表达。作为局部炎症和免疫激活的反映，suPAR作为几种炎症性疾病潜在的预后生物标志物已引起关注。事实上，在许多疾病中，包括癌症、糖尿病、心血管疾病、肾脏疾病和炎症性疾病，较高的suPAR浓度与疾病严重程度、疾病复发和死亡率相关。我们的综述描述并讨论了有关suPAR作为不同自身免疫性风湿性和非风湿性疾病生物标志物的潜在作用的相关文献。
